Value of serum sCD164 and FGF9 levels in evaluating the chemotherapy efficacy and prognosis of advanced non-small cell lung cancer patients
10.3969/j.issn.1673-4130.2024.24.007
- VernacularTitle:血清sCD164、FGF9水平对晚期非小细胞肺癌患者化疗疗效及预后的评估价值
- Author:
Bolin FENG
1
;
Jing CHANG
;
Xin LIU
Author Information
1. 西安交通大学第一附属医院榆林医院呼吸与危重症医学科,陕西榆林 719000
- Keywords:
non-small cell lung cancer;
soluble CD164;
fibroblast growth factor 9;
chemotherapy ef-ficacy;
prognosis
- From:
International Journal of Laboratory Medicine
2024;45(24):2977-2982
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the relationship between the levels of serum soluble CD164(sCD164)and fibro-blast growth factor 9(FGF9)in patients with advanced non-small cell lung cancer(NSCLC)and the chemo-therapy efficacy and the value in evaluating the prognosis.Methods A total of 121 patients with advanced NSCLC(NSCLC group)admitted to the hospital from January 2020 to December 2022 and 70 healthy individ-uals who underwent physical examinations during the same period(control group)were selected.Enzyme linked immunosorbent assay was used to detect serum levels of sCD164 and FGF9.Receiver operating charac-teristic curve was used to analyze the value of serum sCD164 and FGF9 in predicting the efficacy of chemo-therapy in advanced NSCLC patients.Kaplan-Meier curves and multivariate COX regression were used to ana-lyze the relationship between serum sCD164,FGF9 levels and the prognosis of advanced NSCLC patients.Re-sults The serum levels of sCD164 and FGF9 in the NSCLC group were significantly higher than those in the control group(P＜0.05).The serum levels of sCD164 and FGF9 in patients with TNM stage Ⅳ and low dif-ferentiation were significantly higher than those in patients with TNM stage Ⅲ b and high differentiation(P＜0.05).The serum sCD164 and FGF9 levels in the chemotherapy ineffective group were significantly higher than those in the chemotherapy effective group(P＜0.05).The area under the curve of serum sCD164 and FGF9 combined for predicting chemotherapy efficacy in advanced NSCLC patients was 0.955,which was high-er than 0.852 and 0.876 of single index(P＜0.05).The 1-year cumulative survival rates in the sCD164 high level group and the FGF9 high level group were significantly lower than those in the sCD164 low level group and the FGF9 low level group,respectively(P＜0.05).TNM stage Ⅳ,low differentiation degree,high level of sCD164,and high level of FGF9 were risk factors affecting the prognosis of advanced NSCLC patients(P＜0.05).Conclusion The serum levels of sCD164 and FGF9 are elevated in patients with advanced NSCLC,which are associated with tumor TNM staging,differentiation,and chemotherapy efficacy,and are independent risk factors affecting the prognosis of patients with advanced NSCLC.
